Volume 95 Issue 6 | p. 13 | Concentrates
Issue Date: February 6, 2017

Vividion launches out of Scripps

Department: Business
Keywords: start-ups, drug discovery, chemical proteomics, Baran, Yu, Scripps

Vividion Therapeutics has launched based on small-molecule drug discovery technology from three Scripps Research Institute scientists. Backed by $50 million in venture capital funding, Vividion combines a platform for proteome-wide ligand and target discovery from Benjamin F. Cravatt with synthetic chemistry from Phil S. Baran and Jin-Quan Yu. Much drug discovery involves screening of compound libraries using a single target-specific assay. Vividion, in contrast, evaluates compounds in native biological systems, such as human immunocytes and cancer cell lines, so promising protein-ligand interactions are identified amid the entire proteome and in the context of actual protein function.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment